Preclinical evaluation of [¹¹¹ In]-DOTA-trastuzumab for clinical trials.

@article{Alirezapour2014PreclinicalEO,
  title={Preclinical evaluation of [¹¹¹ In]-DOTA-trastuzumab for clinical trials.},
  author={Behrouz Alirezapour and Amir Reza Jalilian and Saeed Rajabifar and Mohammad Reza Mirzaii and Sedigheh Moradkhani and Mehraban Pouladi and Gholamreza Aslani},
  journal={Journal of cancer research and therapeutics},
  year={2014},
  volume={10 1},
  pages={112-20}
}
CONTEXT Herceptin and its fragments have been radiolabeled and used in the imaging of human epidermal growth factor receptor 2 (HER2)/neu-positive tumors and development of diagnostic kits is of great importance in radiopharmacy. AIMS In this study, ¹¹¹ In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-trastuzumab (¹¹¹ In-DOTA-trastuzumab) was… CONTINUE READING